Beth LeBow

Davis Polk advised the underwriters in connection with an initial public offering of 9,315,000 shares of common stock of Berkeley Lights, Inc. at $22.00 per share (which includes the…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by NetApp, Inc. of $750 million aggregate principal amount of its 1.875%…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Applied Materials, Inc. of $750 million aggregate principal amount of its 1.750% notes due 2030 and $750…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection with a $110.5 million SEC-registered common stock offering by…

Davis Polk advised CrowdStrike Holdings, Inc. on its SEC-registered initial public offering of 20,700,000 shares of Class A common stock for an aggregate price to the public of…

Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…